CN1981779A - 黄甘组合物及其制备方法 - Google Patents
黄甘组合物及其制备方法 Download PDFInfo
- Publication number
- CN1981779A CN1981779A CNA2006101634758A CN200610163475A CN1981779A CN 1981779 A CN1981779 A CN 1981779A CN A2006101634758 A CNA2006101634758 A CN A2006101634758A CN 200610163475 A CN200610163475 A CN 200610163475A CN 1981779 A CN1981779 A CN 1981779A
- Authority
- CN
- China
- Prior art keywords
- baicalin
- group
- xanthosine
- composition
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 112
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 title description 93
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 title description 93
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 title description 93
- 238000004519 manufacturing process Methods 0.000 title description 5
- 239000003814 drug Substances 0.000 claims abstract description 34
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 24
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 24
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 24
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 24
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 119
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 99
- 229960003321 baicalin Drugs 0.000 claims description 99
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 99
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 claims description 66
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims description 62
- 238000002347 injection Methods 0.000 claims description 56
- 239000007924 injection Substances 0.000 claims description 56
- 238000002360 preparation method Methods 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 11
- 208000019423 liver disease Diseases 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 125000001477 organic nitrogen group Chemical group 0.000 claims description 4
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- 150000001621 bismuth Chemical class 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- XDQITMCFPPPMBC-TUANDBMESA-N scutelloside Natural products OC[C@H]1O[C@@H](O[C@@H]2O[C@@H]3C[C@H]4[C@H](O)[C@@H](O)[C@@](O)(CO3)[C@@H]24)[C@H](O)[C@@H](O)[C@@H]1O XDQITMCFPPPMBC-TUANDBMESA-N 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
- 241000700159 Rattus Species 0.000 description 27
- 239000004471 Glycine Substances 0.000 description 26
- 210000004185 liver Anatomy 0.000 description 25
- 239000008215 water for injection Substances 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 23
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 239000008187 granular material Substances 0.000 description 21
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 16
- 229960001305 cysteine hydrochloride Drugs 0.000 description 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 14
- 229920002472 Starch Polymers 0.000 description 14
- 235000019359 magnesium stearate Nutrition 0.000 description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 14
- 239000008108 microcrystalline cellulose Substances 0.000 description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 208000006454 hepatitis Diseases 0.000 description 13
- 239000002775 capsule Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 235000001727 glucose Nutrition 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 10
- 229930182817 methionine Natural products 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 9
- 208000005374 Poisoning Diseases 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 229960004397 cyclophosphamide Drugs 0.000 description 9
- 238000007689 inspection Methods 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 231100000572 poisoning Toxicity 0.000 description 9
- 230000000607 poisoning effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 229930195725 Mannitol Natural products 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 231100000283 hepatitis Toxicity 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 235000010355 mannitol Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000011265 semifinished product Substances 0.000 description 8
- 239000008227 sterile water for injection Substances 0.000 description 8
- 206010019668 Hepatic fibrosis Diseases 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 6
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- 231100000753 hepatic injury Toxicity 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 241000272525 Anas platyrhynchos Species 0.000 description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 description 5
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 5
- 241000725618 Duck hepatitis B virus Species 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 5
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 229940023488 pill Drugs 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 231100000111 LD50 Toxicity 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- -1 absorption carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000005262 decarbonization Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000009287 sand filtration Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 241000272522 Anas Species 0.000 description 1
- JZVZLMSUWQYJRJ-UHFFFAOYSA-N C1(=CC=CC=C1)O.[K].[Br] Chemical compound C1(=CC=CC=C1)O.[K].[Br] JZVZLMSUWQYJRJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 重量配比(g+g) | 剂量mg/kg | ALT(U/L) | AST(U/L) | T.Bil(μmol/L) | Alb(g/L) |
空白对照组模型组黄芩苷组甘草酸二铵组黄苷组合物组(黄芩苷+甘草酸二铵) | ----2000+102000+201000+201000+40500+40500+80500+100250+100250+150250+200250+400125+400125+80060+800 | --120120120120120120120120120120120120120120120120 | 37.2±5.662.4±11.2##44.9±9.1*41.4±8.2*40.8±7.9**40.7±7.3**40.1±6.9**39.8±6.4**38.5±6.1**38.7±6.3**38.6±5.9**38.2±5.7**38.3±5.8**38.3±5.6**39.4±5.8**39.5±5.9**39.8±6.2**40.3±7.4** | 157.2±16.4187.8±16.4##182.3±9.9*175.9±8.6*166.5±8.3**165.9±8.1**164.8±7.9**163.5±7.6**159.4±7.3**159.7±7.1**159.3±6.7**159.8±6.1**159.5±6.2**159.4±6.4**160.8±6.3**161.2±6.9**162.9±7.2**163.8±7.4** | 0.32±0.050.87±0.19##1.71±0.29*0.66±0.28*0.55±0.20**0.52±0.19**0.49±0.16**0.47±0.15**0.38±0.13**0.38±0.10**0.39±0.09**0.38±0.06**0.38±0.07**0.39±0.05**0.41±0.08**0.43±0.11**0.47±0.13**0.52±0.17** | 31.4±2.522.8±3.5##23.9±2.4*25.5±2.3*27.3±2.7**27.9±2.6**28.4±2.4**28.7±2.3**30.1±2.6**30.0±2.4**30.3±2.3**30.2±2.1**30.2±2.4**30.1±2.2**29.6±2.1**29.1±2.3**28.9±2.2**28.1±2.4** |
组别 | 重量配比(g+g) | 剂量mg/kg | 总蛋白 | 白蛋白 | 球蛋白 |
空白对照组模型组黄芩苷组甘草酸单铵组黄苷组合物组(黄芩苷+甘草酸单铵) | ----2000+102000+201000+201000+40500+40500+80500+100250+100250+150250+200250+400125+400125+80060+800 | --120120120120120120120120120120120120120120120120 | 73.8±6.250.7±3.7##54.5±5.1*56.2±4.8*64.3±4.9**66.4±5.2**68.3±5.2**69.5±5.3**71.1±5.4**71.6±5.6**71.0±5.4**71.9±5.7**71.7±5.6**71.6±5.8**70.5±5.6**68.4±5.3**66.5±5.1**64.9±4.9** | 39.2±5.321.4±3.9##24.6±3.9*26.7±3.7*32.8±4.5**33.9±4.6**35.5±4.5**36.2±4.9**38.2±4.8**38.1±5.1**38.2±5.1**38.3±5.2**38.2±5.4**38.4±5.3**37.3±5.1**36.4±4.9**35.8±4.7**34.9±4.6** | 31.2±4.222.1±3.1##24.4±4.6*26.2±4.5*27.1±4.4*27.4±4.2*28.1±4.5**28.4±4.4**30.0±4.5**30.3±4.6**30.1±4.3**30.2±4.1**30.1±4.3**30.3±4.2**29.8±4.2**29.5±4.5**28.7±4.3**27.6±4.6* |
组别 | 重量配比 | 动物数(只) | 给药剂量(mg/kg) | ALT(u/dl) | LTG(mg/g) | MDA(n mol/g) |
空白对照组CCl4对照组黄芩苷组甘草酸二铵组黄甘组合物注射液组(黄芩苷+甘草酸二铵) | ----125mg+10mg150mg+20mg200mg+50mg200mg+100mg250mg+150mg250mg+200mg300mg+250mg400mg+300mg500mg+400mg | 10101010101010101010101010 | -108080808080808080808080 | 235±48586±231**525±183*#513±179*#305±105##&△303±101##&△261±86##&△253±62##&△248±50##&△252±54##&△258±66##&△262±83##&△308±107##&△ | 14±638±15**28±9*#27±8*#21±11##&△19±7##&△15±5##&△13±4##&△12±4##&△14±5##&△14±6##&△15±8##&△20±9##&△ | 43±1086±25**63±15*#61±14*#51±12##&△48±11##&△42±10##&△41±8##&△39±6##&△40±10##&△42±10##&△43±11##&△50±13##&△ |
组别 | 动物数(只) | 给药剂量(mg/kg) | 肝指数(g/100g) | 脾指数(g/100g) |
空白对照组CCl4对照组黄芩苷组甘草酸单铵组黄甘组合物 低剂量注射液组 中剂量高剂量 | 10101010101010 | -108060204060 | 6.22±1.018.36±0.62**7.51±0.72*#7.38±0.75*#6.62±0.80##&△6.58±0.75##&△6.42±0.74##&△ | 0.632±0.1430.730±0.078**0.688±0.045*#0.698±0.053*#0.654±0.053##&△0.640±0.048##&△0.633±0.076##&△ |
组别 | 剂量mg/kg | 治疗前DHBV-DNA滴度 | 治疗后7dDHBV-DNA滴度 | 治疗后14dDHBV-DNA滴度 | 停药后3dDHBV-DNA滴度 |
空白对照组阳性对照组黄芩苷组甘草酸二铵组黄甘低剂量组合中剂量物组高剂量 | -508080406080 | 1.63±0.051.64±0.041.61±0.031.62±0.041.59±0.051.60±0.021.62±0.03 | 1.61±0.040.78±0.14**&&1.35±0.08*&1.31±0.11*&1.03±0.12**&&#△0.98±0.15**&&#△0.91±0.16**&&#△ | 1.62±0.040.76±0.12**&&1.32±0.06*&1.30±0.09*&0.98±0.09**&&#△0.90±0.13**&&#△0.84±0.15**&&#△ | 1.64±0.031.62±0.041.42±0.05*&1.36±0.06*&1.04±0.10**&&#△1.01±0.08**&&#△0.95±0.13**&&#△ |
组别 | 剂量mg/kg | ALT(U/L) | AST(U/L) | TG(mmol/L) | TC(mmol/L) | MDA(mmol/L) |
对照组模型组黄芩苷组甘草酸二铵黄甘低组合中物组高 | --1201206090120 | 46.44±4.5759.37±10.09##55.69±15.75*53.64±8.72*49.31±4.24**48.34±3.94**47.62±4.01** | 201.23±29.38298.08±31.36##266.31±67.20*254.32±46.73*237.21±29.31**229.68±24.62**218.94±21.30** | 0.71±0.130.85±0.19#0.82±0.22*0.80±0.19*0.78±0.14*0.75±0.12*0.73±0.11* | 1.69±0.282.23±0.43##2.10±0.36*2.02±0.29*1.90±0.26*1.85±0.21**1.73±0.24** | 8.00±2.3911.87±2.54##10.94±2.26*10.03±2.01*8.48±1.32**8.32±1.01**8.11±0.68** |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101634758A CN1981779B (zh) | 2005-12-05 | 2006-12-04 | 黄甘组合物及其制备方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510045303.6 | 2005-12-05 | ||
CN200510045303 | 2005-12-05 | ||
CN2006101634758A CN1981779B (zh) | 2005-12-05 | 2006-12-04 | 黄甘组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1981779A true CN1981779A (zh) | 2007-06-20 |
CN1981779B CN1981779B (zh) | 2010-05-19 |
Family
ID=38164810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101634758A Expired - Fee Related CN1981779B (zh) | 2005-12-05 | 2006-12-04 | 黄甘组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1981779B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101837046A (zh) * | 2010-05-27 | 2010-09-22 | 辽宁中医药大学 | 一种抗病毒中药制剂及其制备方法 |
CN106265913A (zh) * | 2016-08-25 | 2017-01-04 | 江苏天晟药业股份有限公司 | 一种含甘草酸单铵盐的药物组合物及其制备方法和应用 |
CN110538187A (zh) * | 2018-05-28 | 2019-12-06 | 北京大学 | Cpt1激活剂 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481805A (zh) * | 2003-07-14 | 2004-03-17 | 军 王 | 一种治疗肝炎的药物及其制备方法 |
CN1526399A (zh) * | 2003-09-25 | 2004-09-08 | 肖广常 | 注射用甘草酸二铵冻干粉针剂及其制备方法 |
CN1726960A (zh) * | 2004-07-27 | 2006-02-01 | 南京宇道科技开发有限公司 | 一种治疗慢性肝炎的有效部位组合物及其制剂和用途 |
-
2006
- 2006-12-04 CN CN2006101634758A patent/CN1981779B/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101837046A (zh) * | 2010-05-27 | 2010-09-22 | 辽宁中医药大学 | 一种抗病毒中药制剂及其制备方法 |
CN106265913A (zh) * | 2016-08-25 | 2017-01-04 | 江苏天晟药业股份有限公司 | 一种含甘草酸单铵盐的药物组合物及其制备方法和应用 |
CN110538187A (zh) * | 2018-05-28 | 2019-12-06 | 北京大学 | Cpt1激活剂 |
Also Published As
Publication number | Publication date |
---|---|
CN1981779B (zh) | 2010-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103893247A (zh) | 药物组合物及其制备方法和用途 | |
CN103893258A (zh) | 含有广金钱草总黄酮的口服固体制剂及其应用 | |
CN1985864B (zh) | 一种主要由甘草酸或其盐、人参和灵芝制成的药物组合物 | |
CN106667915A (zh) | 一种用于治疗仔猪腹泻的黄芩苷铝干混悬剂 | |
CN100584348C (zh) | 一种抗肝炎的药物组合物 | |
CN1981779B (zh) | 黄甘组合物及其制备方法 | |
CN1985927A (zh) | 一种主要用于肝脏疾病的药物组合物 | |
CN111494564B (zh) | 一种复合型保肝解酒片的制备方法 | |
CN1985873B (zh) | 甘草酸或其盐、人参和黄芪的药物组合物 | |
CN100537593C (zh) | 甘草酸复盐及其制剂 | |
CN101152233B (zh) | 一种瓜蒌和银杏叶的药物组合物 | |
CN1961898B (zh) | 一种复方半枝莲抗肿瘤药物组合物及其制备方法 | |
CN100482266C (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN101199806A (zh) | 一种治疗腹泻的药物及其制备方法和质量控制方法 | |
CN1686424A (zh) | 一种含有黄芩和柴胡的药物组合物及其制备方法 | |
CN1969922B (zh) | 一种复方药物组合物及其制备方法 | |
CN1985987B (zh) | 甘草酸或其盐和还原型谷胱甘肽的药物组合物 | |
CN1977888B (zh) | 一种由黄芩苷、灵芝和丹参制成的药物组合物 | |
CN100534476C (zh) | 由板蓝根和射干制成的药物组合物及其制备方法和用途 | |
CN100574764C (zh) | 一种抗肝炎药物组合物及其制备方法 | |
CN101081227B (zh) | 甘草酸二铵的组合物 | |
CN101190937B (zh) | 具有保肝活性的化合物 | |
CN100482245C (zh) | 板蓝根和黄芩苷的药物组合物 | |
CN108542940A (zh) | 一种中药组合物在制备预防和/或治疗手足口病药物中的应用 | |
CN1969924B (zh) | 水飞蓟宾和板蓝根的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: XUAN ZHU SHANDONG MEDICINE TECHNOLOGY CO. Free format text: FORMER OWNER: HUANG ZHENHUA Effective date: 20080523 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080523 Address after: Post encoding No. 2518 block A, Tianchen Avenue Ji'nan High-tech Development Zone in Shandong Province: 250101 Applicant after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Post encoding No. 2518 block A, Dongchen street, Ji'nan high tech Development Zone in Shandong Province: 250101 Applicant before: Huang Zhenhua |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAIAN SUSHI TECHNOLOGY TRANSFORMATION CENTER CO., Free format text: FORMER OWNER: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD. Effective date: 20130930 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 226601 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130930 Address after: 226601 No. 8 Yingbin Road, software park, Haian County, Jiangsu Province Patentee after: Haian Su Fu Technology Transfer Center Co., Ltd. Address before: Tianchen Avenue in Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 block A Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100519 Termination date: 20191204 |
|
CF01 | Termination of patent right due to non-payment of annual fee |